Cargando...
The dark side of Toll-like receptor signaling: TLR9 activation limits the efficacy cancer radiotherapy
Radiation therapy is potentially immunogenic yet it rarely generates long-term antitumor effects. We have recently demonstrated that Toll-like receptor 9 (TLR9) jump-starts the signal transduction and activator of transcription 3 (STAT3)-dependent vascularization and regrowth of tumors that recur up...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Landes Bioscience
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4203530/ https://ncbi.nlm.nih.gov/pubmed/25340001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.27894 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|